Amyloid Cardiopathy and Aortic Stenosis

Area of Science:

• Cardiology
• Cardiovascular Medicine
• Amyloidosis Research

Background:

• Cardiac amyloidosis (CA) is increasingly diagnosed, particularly in older patients with heart failure with preserved ejection fraction.
• A significant subset of patients with severe aortic stenosis (AS) also have transthyretin amyloid cardiomyopathy (CA-ATTR), impacting diagnosis, prognosis, and treatment.
• High suspicion for CA is indicated by biventricular hypertrophy (≥15 mm) and specific clinical 'red flags'.

Discussion:

• Diagnosing CA, with or without AS, is complex and requires careful assessment of AS severity.
• Diagnostic accuracy is enhanced by specific tests like bone scintigraphy and the absence of monoclonal light chains.
• Genetic testing is crucial for differentiating senile and hereditary transthyretin (ATTR) types of CA.

Key Insights:

• Pharmacological management of CA with heart failure requires cautious use of certain medications like beta-blockers and ACE inhibitors, with diuretics used to maintain euvolemia.
• Aortic valve replacement (AVR), either transcatheter (TAVR) or surgical (SAVR), is recommended for severe AS associated with CA, with TAVR showing favorable comparative results.
• Emerging pharmacological agents targeting CA-ATTR hold promise for significantly altering the management landscape of ATTR amyloidosis.

Outlook:

• Further comparative studies on TAVR versus SAVR are needed to refine treatment strategies for AS in CA patients.
• Continued research into novel pharmacological agents will likely transform the treatment of ATTR amyloidosis.
• Improved diagnostic pathways and targeted therapies are expected to enhance outcomes for patients with cardiac amyloidosis.